Mapping pro- and antiangiogenic factors on the surface of prostasomes of normal and malignant cell origin

Prostate

Volumn 70, Issue 8, 2010, Pages 834-847

  Babiker, Adil A ^a   Magnusson, Peetra U ^a   Ronquist, Gunnar ^a   Nilsson, Bo ^a   Ekdahl, Kristina Nilsson ^a,b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LINNAEUS UNIVERSITY   (Sweden)

Author keywords

DU145; Endostatin; Endothelin 1; LNCaP; PC 3; Prostasomes; Prostate cancer; Thrombospondin 1; VEGF

Indexed keywords

ENDOSTATIN; ENDOTHELIN 1; THROMBOSPONDIN 1; THYMIDINE; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CANCER CELL; CELL FUNCTION; CONFOCAL LASER MICROSCOPY; ENDOTHELIUM CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; MALE; MEMBRANE VESICLE; PRIORITY JOURNAL; PROSTASOME; PROSTATE CANCER; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SEMINAL PLASMA; ANALYSIS OF VARIANCE; CELL PROLIFERATION; CONFOCAL MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE; SECRETORY VESICLE; SPERM; TUMOR CELL LINE; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOSTATINS; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; MALE; MICROSCOPY, CONFOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; SECRETORY VESICLES; SEMEN; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952314185     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21117     Document Type: Article

References (80)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;4:58-61. (Pubitemid 19115892)
3. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 2005;109(3):227-241.
4. Suto K, Yamazaki Y, Takashi Morita T, Mizuno H. Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: Insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem 2005;280(3):2126-2131.
5. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219(4587):983-985.
6. Ronquist G, Brody I. The prostasome: Its secretion and function in man. Biochim Biophys Acta 1985;822(2):203-218.
7. Stegmayr B, Brody I, Ronquist G. A biochemical and ultrastructural study on the endogenous protein kinase activity of secretory granule membranes of prostatic origin in human seminal plasma. J Ultrastruct Res 1982;78(2):206-214. (Pubitemid 12128580)
8. Fernandez JA, Heeb MJ, Radtke KP, Griffin JH. Potent blood coagulant activity of human semen due to prostasome-bound tissue factor. Biol Reprod 1997;56(3):757-763.
9. Stegmayr B, Ronquist G. Promotive effect on human sperm progressive motility by prostasomes. Urol Res 1982;10(5):253-257. (Pubitemid 13253597)
10. Fabiani R, Johansson L, Lundkvist O, Ulmsten U, Ronquist G. Promotive effect by prostasomes on normal human spermatozoa exhibiting no forward motility due to buffer washings. Eur J Obstet Gynecol Reprod Biol 1994;57(3):181-188.
11. Carlsson L, Pahlson C, Bergquist M, Ronquist G, Stridsberg M. Antibacterial activity of human prostasomes. Prostate 2000; 44(4):279-286.
12. Saez F, Motta C, Boucher D, Grizard G. Antioxidant capacity of prostasomes in human semen. Mol Hum Reprod 1998;4(7):667-672.
13. Sahlen G, Ahlander A, Frost A, Ronquist G, Norlen BJ, Nilsson BO. Prostasomes are secreted from poorly differentiated cells of prostate cancer metastases. Prostate 2004;61(3):291-297. (Pubitemid 39350452)
14. Babiker AA, Nilsson B, Ronquist G, Carlsson L, Ekdahl KN. Transfer of functional prostasomal CD59 of metastatic prostatic cancer cell origin protects cells against complement attack. Prostate 2005;62(2):105-114. (Pubitemid 40096776)
15. Babiker AA, Nilsson B, Ronquist G, Ekdahl KN. Overexpression of ecto-protein kinases in prostasomes of metastatic cell origin. Prostate 2006;66(7):675-686.
16. Babiker AA, Hamad OA, Sanchez J, Ronquist G, Nilsson B, Ekdahl KN. Prothrombotic effect of prostasomes of metastatic cell and seminal origin. Prostate 2007;67:378-388. (Pubitemid 46341078)
17. Babiker AA, Ekdahl KN, Nilsson B, Ronquist G. Prothombotic effects of prostasomes isolated from prostatic cancer cell lines and seminal plasma. Semin Thromb Hemost 2007;33:80-86. (Pubitemid 46184035)
18. van Moorselaar RJA, Voest EE. Angiogenesis in prostate cancer: Its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 2002;197:239-250.
19. Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma. Thromb Haemost 2004;92(1):185-190. (Pubitemid 39010882)
20. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21(3):274-281. (Pubitemid 8283045)
21. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17(1):16-23. (Pubitemid 9239413)
22. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43(4):1809-1818.
23. Babiker AA, Ronquist G, Nilsson UR, Nilsson B. Transfer of prostasomal CD59 to CD59-deficient red blood cells results in protection against complement-mediated hemolysis. Am J Reprod Immunol 2002;47(3):183-192.
24. Carlsson L, Nilsson O, Larsson A, Stridsberg M, Sahlen G, Ronquist G. Characteristics of human prostasomes isolated from three different sources. Prostate 2003;54(4):322-330.
25. Nilsson BO, Lennartsson L, Carlsson L, Nilsson S, Ronquist G. Expression of prostasome-like granules by the prostate cancer cell lines PC3, Du145 and LnCaP grown in monolayer. Ups J Med Sci 1999;104(3):199-206.
26. Arvidson G, Ronquist G, Wikander G, Ojteg AC. Human prostasome membranes exhibit very high cholesterol/phospholipid ratios yielding high molecular ordering. Biochim Biophys Acta 1989;984(2):167-173.
27. Babst M. A protein's final ESCRT. Traffic 2005;6(1):2-9.
28. Sahlen GE, Egevad L, Ahlander A, Norlen BJ, Ronquist G, Nilsson BO. Ultrastructure of the secretion of prostasomes from benign and malignant epithelial cells in the prostate. Prostate 2002;53(3):192-199.
29. Ronquist G, Nilsson BO, Hjerten S. Interaction between prostasomes and spermatozoa from human semen. Arch Androl 1990;24(2):147-157.
30. Arienti G, Carlini E, Saccardi C, Palmerini CA. Role of human prostasomes in the activation of spermatozoa. J Cell Mol Med 2004;8(1):77-84.
31. Rooney IA, Atkinson JP, Krul ES, Schonfeld G, Polakoski K, Saffitz JE, Morgan BP. Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis. J Exp Med 1993;177(5):1409-1420.
32. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25(4):581-611. (Pubitemid 39099316)
33. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth family of proteins. Endocr Rev 1992;13:18-32.
34. Detmar M, Velasco P, Richard L, Claffey KP, Streit M, Riccardi L, Skobe M, Brown LF. Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinoma. Am J Pathol 2000;156(1):159-167.
35. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane EF, Birkhead JR, Olson BR, Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285.
36. Dixelius J, Cross MJ, Matsumoto T, Claesson-Welsh L. Endostatin action and intracellular signaling: β-catenin as potential target? Cancer Lett 2003;196:1-12.
37. Eriksson K, Magnusson P, Dixelius J, Claesson-Welsh L, Cross MJ. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathway. FEBS Lett 2003;536: 19-24.
38. Suleyman E, Kilic N, Wurmbach JH, Ebrahimnejad A, Fernando M, Sevinc S, Kilic E, Chalajour F, Fiedler W, Lauke H, Lamszus K, Hammerer P, Weil J, Herbst H, Folkman J. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 2001;4:193-206.
39. Suzuki M, Iizasa T, Ko E, Baba M, Saitoh Y, Shibuya K, Sekine Y, Yoshida S, Hiroshima K, Fujisawa T. Seru mendostatin correlates with progression and prognosis of non-small lung cancer. Lung Cancer 2002;35:29-34.
40. Wrobel T, Mazur G, Kapelko K, Kuliczkowski K. Endostatin serum level in acute myeloid leukemia. Neoplasma 2005; 52(2):182-184.
41. Raymond L, Elihu E, Yu S, Despa S, Kantarjian H, Beran M, Maushouri T, Quackenbuch RC, Keating M, Albitar M. Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer 2002;94:14-17.
42. Bono P, Teerenhovl L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 2003;97:2767-2775. (Pubitemid 36605144)
43. Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander HR Jr, Libutti SK. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 2000;6:4628-4634.
44. Lamoreaux WJ, Fitzgerald MEC, Reiner A, Hasty KA, Charles ST. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998;55:29-42. (Pubitemid 28368411)
45. Unemori EN, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992;153: 557-562.
46. Zucker S, Mirza H, Conner CE, Lorenz AF, Drews MH, Bahou WF, Jesty J. Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: Conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer 1998;75:780-786. (Pubitemid 28145828)
47. Stetler-Stevenson WG. The role of matrix metalloproteinases in tumor invasion, metastasis and angiogenesis. Surg Oncol Clin N Am 2001;10(2):383-392.
48. Bellezza I, Aisa MC, Palazzo R, Costanzi E, Mearini E, Minelli A. Extracellular matrix degrading enzymes at the prostasome surface. Prostate Cancer Prostatic Dis 2005;8:344-348. (Pubitemid 43078169)
49. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528-539.
50. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-890. (Pubitemid 39472954)
51. Lilja H. Biology of prostate-specific antigen. Urology 2003; 62(Suppl 1):27-33.
52. Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2007;67:312-329.
53. Williams SA, Merchant RF, Garret-Mayer E, Isaacs JT, Buckley JT, Denmeade SR.Aprostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007;99(5):376-385.
54. Kim YM, Jang JW, Lee OH, Yeon J, Y CE, Kim KM, Lee ST, Kwon YG. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000;60:5410-5413.
55. Lee SJ, Jang JW, Kim YM, Lee HI, Jeon JY, Kwon YG, Lee ST. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett 2002;519:147-152.
56. Mosher DF. Physiology of thrombospondin. Annu Rev Med 1990;41:85-97.
57. McPherson J, Sage H, Bornstein P. Isolation and characterization of a glycoprotein secreted by aortic endothelial cells in culture. J Biol Chem 1981;256(21):11330-11336.
58. Taraboletti G, Morbidelli L, Donnini S, Parenti A, Granger HJ, Giavazzi R, Ziche M. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J 2000;14:1674-1676.
59. Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci 1995;108:797-809.
60. Qian X, Wang TN, Rothman VL, Nicosia RF, Tuszynski GP. Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells. Exp Cell Res 1997;235:403-412. (Pubitemid 27398399)
61. Ribatti D, Conconi MT, Nussdorfer GG. Nonclassic endogenous novel regulators of angiogenesis. Pharmacol Rev 2007;59(2): 185-205. (Pubitemid 46855439)
62. Rubanyi GM, Botelho LHP. Endothelins. FASEB J 1991;5:2713-2720.
63. B receptors. Am J Physiol 1995;269(38):H686-H695.
64. Bagnato A, Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008;40:1443-1451.
65. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2002;14(1):44-50. (Pubitemid 36733931)
66. Boldrini L, Gisfredi S, Ursino S, Faviana P, Lucchi M, Melfi F, Mussi A, Basolo F, Fontanini G. Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur J Cancer 2005;41:2828-2835. (Pubitemid 41713120)
67. A receptor antagonism. Br J Cancer 2001;85(11):1759-1763.
68. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1(9):944-949.
69. Nelson JB, Chan-Tack C, Hedican SP, Magnusson SR, Opgenorth TJ, Bova GS, Simons JW. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663-668.
70. Casey ML, Byrd W, MacDonald PC. Massive amount of immunoreactive endothelin in human seminal fluid. J Clin Endoc Metabol 1992;74:223-225.
71. Granchi S, Brocchi S, Bonaccorsi L, Baldi E, Vinci MC, Forti G, Serio M, Maggi M. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 2001; 49:267-277. (Pubitemid 33117002)
72. Abdulkadir SA, Carvalhal GF, Kaleem Z, Kisiel W, Humphrey PA, Catalona WJ, Milbrandt J. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000; 31(4):443-447. (Pubitemid 30262866)
73. Abe K, Shoji M, Chen J, Bierhaus A, Danave I, Micko C, Casper K, Dillehay DL, Nawroth PP, Rickles FR. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999; 96(15):8663-8668.
74. Ollivier V, Bentolila S, Chabbat J, Hakim J, De Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998;91(8):2698-2703. (Pubitemid 28227518)
75. Belting M, Dorrell MI, Sandgren S, Aguilar E, Ahmed J, Dorfleutner A, Carmeliet P, Mueller BM, Friedlander M, Ruf W. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med 2004;10(5):502-509.
76. Delves GH, Stewart AB, Lwaleed BA, Cooper AJ. In vitro inhibition of angiogenesis by prostasomes. Prostate Cancer Prostatic Dis 2005;8:174-178.
77. Delves GH, Goyal A, Lwaleed BA, Cooper AJ. Seminal prostasomes inhibit the angiogenesis activity of rat aortic rings. Prostate Cancer Prostatic Dis 2006;9:444-447.
78. Carlsson L, Lennartsson L, Nilsson BO, Nilsson S, Ronquist G. Growth-inhibitory effect of prostasomes on prostatic cancer cell lines in culture. Eur Urol 2000;6(10):883-891.
79. Delves GH, Stewart AB, Cooper AJ, Lwaleed BA. Prostasomes, angiogenesis, and tissue factor. Semin Thromb Hemost 2007; 33(1):75-79.
80. Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, Gho YS. Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res 2002;62(21):6312-6317.